You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Carbamazepine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for carbamazepine and what is the scope of patent protection?

Carbamazepine is the generic ingredient in eight branded drugs marketed by Apotex Inc, Nostrum Labs Inc, Taro, Teva Pharms, Takeda Pharms Usa, Validus Pharms, Lundbeck Pharms Llc, Chartwell Rx, Novitium Pharma, Novartis, Jubilant Cadista, Taro Pharm Inds, Torrent Pharms, Teva, Ajanta Pharma Ltd, Amneal Pharms, Anbison Lab, Apotex, Cspc Ouyi, Riconpharma Llc, Sciecure Pharma Inc, Umedica, Unique Pharm, Zhejiang Jiuzhou, Zydus Pharms, Actavis Elizabeth, Bionpharma, Inwood Labs, Pliva, Rk Pharma, Unichem, Usl Pharma, and Warner Chilcott, and is included in forty-five NDAs. There are eight patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Carbamazepine has seventy-eight patent family members in twenty-one countries.

There are twenty-seven drug master file entries for carbamazepine. Forty-six suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for carbamazepine

See drug prices for carbamazepine

Drug Sales Revenue Trends for carbamazepine

See drug sales revenues for carbamazepine

Recent Clinical Trials for carbamazepine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alexion Pharmaceuticals, Inc.Phase 1
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyPhase 1
Aligos TherapeuticsPhase 1

See all carbamazepine clinical trials

Generic filers with tentative approvals for CARBAMAZEPINE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up300MGCAPSULE, EXTENDED RELEASE; ORAL
⤷  Sign Up⤷  Sign Up200MGCAPSULE, EXTENDED RELEASE; ORAL
⤷  Sign Up⤷  Sign Up100MGCAPSULE, EXTENDED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for carbamazepine
Anatomical Therapeutic Chemical (ATC) Classes for carbamazepine
Paragraph IV (Patent) Challenges for CARBAMAZEPINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EQUETRO Extended-release Capsules carbamazepine 100 mg 021710 1 2014-05-23
EQUETRO Extended-release Capsules carbamazepine 200 mg and 300 mg 021710 1 2007-08-21
CARBATROL Extended-release Capsules carbamazepine 100 mg and 200 mg 020712 1 2006-02-02
TEGRETOL-XR Extended-release Tablets carbamazepine 100 mg 020234 1 2005-12-30

US Patents and Regulatory Information for carbamazepine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cspc Ouyi CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 213311-002 Apr 13, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex Inc CARBAMAZEPINE carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 078986-002 Nov 25, 2011 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Jubilant Cadista CARBAMAZEPINE carbamazepine TABLET, CHEWABLE;ORAL 071940-001 Feb 1, 1988 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-001 Mar 25, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Taro TERIL carbamazepine SUSPENSION;ORAL 076729-001 Sep 20, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Taro CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 078115-001 Mar 31, 2009 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 213159-002 Mar 8, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for carbamazepine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-002 Dec 10, 2004 ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-001 Mar 25, 1996 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa CARBATROL carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 020712-001 Sep 30, 1997 ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-002 Mar 25, 1996 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa CARBATROL carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 020712-002 Sep 30, 1997 ⤷  Sign Up ⤷  Sign Up
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL carbamazepine TABLET, CHEWABLE;ORAL 018281-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for carbamazepine

Country Patent Number Title Estimated Expiration
Japan 2013040195 NEW PARENTERAL CARBAMAZEPINE FORMULATION ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2020157257 ⤷  Sign Up
South Korea 101314803 ⤷  Sign Up
Portugal 1928464 ⤷  Sign Up
Australia 2013226073 Alkylated cyclodextrin compositions and processes for preparing and using the same ⤷  Sign Up
Japan 6444548 ⤷  Sign Up
Canada 2624463 NOUVELLE PREPARATION A BASE DE CARBAMAZEPINE A ADMINISTRATION PAR VOIE PARENTERALE (NOVEL PARENTERAL CARBAMAZEPINE FORMULATION) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.